Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies
- PMID: 2860972
- DOI: 10.1016/s0092-8674(85)80050-7
Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies
Abstract
Exposure of neu-oncogene-transformed NIH 3T3 cells to monoclonal antibodies reactive with the neu gene product, p185, results in the rapid and reversible loss of both cell-surface and total cellular p185. Although not directly cytotoxic, monoclonal anti-p185 antibody treatment causes neu-transformed NIH 3T3 cells to revert to a nontransformed phenotype, as determined by anchorage-independent growth. Isotype matched control antibodies of an unrelated specificity do not affect p185 levels or colony formation in soft agar by neu-transformed NIH 3T3 cells. Soft agar colony formation by NIH 3T3 cells transformed by ras oncogenes is not affected by anti-p185 antibody treatment. Anchorage-independent growth of cells from the ethylnitrosourea-induced rat neuroblastoma line in which neu was originally detected by DNA transfection is also inhibited in the presence of anti-p185 monoclonal antibodies. Collectively, these results suggest that p185 is required to maintain transformation induced by the neu oncogene.
Similar articles
-
Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.Oncogene. 1988 Apr;2(4):387-94. Oncogene. 1988. PMID: 2896329
-
Downstream signal transduction defects that suppress transformation in two revertant cell lines expressing activated rat neu oncogene.J Biol Chem. 1993 Aug 25;268(24):18136-42. J Biol Chem. 1993. PMID: 7688739
-
Reexpression of neu-encoded oncoprotein counteracts the tumor-suppressing but not the metastasis-suppressing function of E1A.Cancer Res. 1993 Dec 1;53(23):5784-90. Cancer Res. 1993. PMID: 7902209
-
The role of non-ras transforming genes in chemical carcinogenesis.Environ Health Perspect. 1991 Jun;93:33-40. doi: 10.1289/ehp.919333. Environ Health Perspect. 1991. PMID: 1685444 Free PMC article. Review.
-
Biological studies and potential therapeutic applications of monoclonal antibodies and small molecules reactive with the neu/c-erbB-2 protein.Cell Biophys. 1994;24-25:209-18. doi: 10.1007/BF02789231. Cell Biophys. 1994. PMID: 7736525 Review.
Cited by
-
Identification of Genes Predicting Poor Response of Trastuzumab in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer.J Immunol Res. 2022 Jul 27;2022:9529114. doi: 10.1155/2022/9529114. eCollection 2022. J Immunol Res. 2022. PMID: 35935587 Free PMC article.
-
Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia.EMBO J. 1996 Feb 1;15(3):520-7. EMBO J. 1996. PMID: 8599935 Free PMC article.
-
Upregulation of miR-99b-5p Modulates ESR1 Expression as an Adaptive Mechanism to Circumvent Drug Response via Facilitating ER/HER2 Crosstalk.Balkan Med J. 2025 Mar 3;42(2):150-156. doi: 10.4274/balkanmedj.galenos.2025.2024-12-47. Balkan Med J. 2025. PMID: 40033677 Free PMC article.
-
Adaptive Immune Responses and HER2/neu Positive Breast Cancer.Curr Pathobiol Rep. 2013 Mar;1(1):37-42. doi: 10.1007/s40139-012-0001-8. Curr Pathobiol Rep. 2013. PMID: 23420038 Free PMC article.
-
TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins.Mol Cell Biol. 1990 Aug;10(8):4007-15. doi: 10.1128/mcb.10.8.4007-4015.1990. Mol Cell Biol. 1990. PMID: 1695320 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous